BI
RAPT

BVF Inc’s RAPT Therapeutics RAPT Stock Holding History

BVF Inc’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,154,692
Closed -$9.24M – 49
2025
Q2 		$9.24M Sell
1,154,692
-3
-0% -$23 0.33% 32
2025
Q1 		$11.3M Hold
1,154,695
– – 0.46% 32
2024
Q4 		$14.6M Buy
+1,154,695
New +$14.7M 0.49% 33

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BVF Inc's RAPT Position: Q3 2025 in Review

BVF Inc sold out of RAPT Therapeutics (RAPT) in Q3 2025, closing a stake of 1,154,692 shares — an estimated $9.24M sold.

BVF Inc first reported a position in RAPT in Q4 2024 and held it in 3 quarters. The position peaked at $14.6M in Q4 2024. 65 funds tracked by Wall St. Rank hold RAPT as of Q3 2025.

  • BVF Inc reported no remaining RAPT Therapeutics position as of Q3 2025 after selling out during the quarter.
  • BVF Inc sold 1,154,692 RAPT Therapeutics shares in Q3 2025, an estimated $9.24M.
  • BVF Inc first reported a position in RAPT Therapeutics in Q4 2024 and held it in 3 quarters.
  • BVF Inc's RAPT Therapeutics position peaked at $14.6M in Q4 2024.
  • 65 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2025.

Based on BVF Inc's 13F filing for Q3 2025, filed 14 Nov 2025.